A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3.

Trial Profile

A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 23 Jun 2014 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 06 Mar 2013 Results from the second cohort are expected in the second quarter of 2013, according to an Advaxis media release. Enrolment into the high-dose cohort is expected to commence before the end of 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top